Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
sell

Regeneron Pharmaceuticals Inc. sell geldnutzer

Regeneron Pharmaceuticals Inc.
Start price
€437.60
19.11.20 / 50%
Target price
€426.00
19.11.21
Performance (%)
1.19%
End price
€442.80
23.11.20
Summary
This prediction ended on 23.11.20 with a price of €442.80. The SELL prediction by geldnutzer shows the price for Regeneron Pharmaceuticals Inc. slightly increased by 1.19% during the runtime of the prediction. geldnutzer has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y 3y
Regeneron Pharmaceuticals Inc. -1.120% -1.120% 15.386% 105.699%
iShares Core DAX® 1.051% -1.833% 12.822% 15.392%
iShares Nasdaq 100 -0.547% -3.738% 40.625% 42.396%
iShares Nikkei 225® -1.778% -8.115% 16.092% 0.891%
iShares S&P 500 0.002% -2.226% 28.387% 41.095%

According to geldnutzer what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?

Pros
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Small challenges to pay loans and raise capital
Very valuable balance sheet
Top Rating
Very positive Cash Flow expected
Capable Management
Leading role in innovation
Strong uniques
Very differentiated customer and product portfolio
Growths much faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Small Risks for its business
Market Leader or Top 3
Very Future proof/growth oriented business model
Could be worthwhile Investment >10% per year
Small cyclical dependencies
Known brand
Cons

Comments by geldnutzer for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Sell
Perf. (%) 1.19%
Target price 426.000
Change
Ends at 19.11.21

Sell mit Kursziel 426,0

geldnutzer 
0
Report Share
19.11.20
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) 1.19%
Target price 426.000
Change
Ends at 19.11.21

Sell beendet

geldnutzer 
0
Report Share
23.11.20

Stopped prediction by geldnutzer for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€442.80
23.11.20
€555.00
23.11.21
29.97%
24.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
geldnutzer 
23.11.20 80%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€453.60
01.09.17
€526.00
04.11.21
-3.53%
19.11.20

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
geldnutzer 
15.08.19 50%